BetterScholar BetterScholar
9
Role
Title
Level Year L/R
🦁 Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein.
S. Mori, Lina Wang, T. Takeuchi, T. Kanda
7 2004
7
🦁
🐜 In Vivo and In Vitro Studies Suggest a Possible Involvement of HPV Infection in the Early Stage of Breast Carcinogenesis via APOBEC3B Induction
11 auth. K. Ohba, K. Ichiyama, Misako Yajima, N. Gemma, Masaru Nikaido, Qingqing Wu, ... PeiPei Chong, S. Mori, Rain Yamamoto, J. Wong, N. Yamamoto
6 2014
6
🐜
🦁 Human Papillomavirus 16 E6 Upregulates APOBEC3B via the TEAD Transcription Factor
7 auth. S. Mori, T. Takeuchi, Y. Ishii, T. Yugawa, T. Kiyono, H. Nishina, ... I. Kukimoto
5 2017
5
🦁
🦁 Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers
S. Mori, Sari Nakao, I. Kukimoto, Rika Kusumoto‐Matsuo, K. Kondo, T. Kanda
5 2011
5
🦁
🐜 Within-Host Variations of Human Papillomavirus Reveal APOBEC Signature Mutagenesis in the Viral Genome
14 auth. Y. Hirose, Mamiko Onuki, Yuri Tenjimbayashi, S. Mori, Y. Ishii, T. Takeuchi, Nobutaka Tasaka, T. Satoh, T. Morisada, T. Iwata, ... S. Miyamoto, Koji Matsumoto, A. Sekizawa, I. Kukimoto
5 2018
5
🐜
🐜 The immediate early gene 1 product of human cytomegalovirus is sufficient for up-regulation of interleukin-8 gene expression.
9 auth. T. Murayama, N. Mukaida, H. Sadanari, N. Yamaguchi, K. Khabar, J. Tanaka, ... K. Matsushima, S. Mori, Y. Eizuru
5 2000
5
🐜
🦁 Identification of APOBEC3B promoter elements responsible for activation by human papillomavirus type 16 E6.
S. Mori, T. Takeuchi, Y. Ishii, I. Kukimoto
5 2015
5
🦁
🐜 APOBEC3A and 3C decrease human papillomavirus 16 pseudovirion infectivity.
17 auth. M. Ahasan, K. Wakae, Zhe Wang, K. Kitamura, Guangyan Liu, Miki Koura, Mieko Imayasu, N. Sakamoto, Kousei Hanaoka, Mitsuhiro Nakamura, ... S. Kyo, S. Kondo, H. Fujiwara, T. Yoshizaki, S. Mori, I. Kukimoto, M. Muramatsu
5 2015
5
🐜
🐬 Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody.
Y. Ishii, Keiko Tanaka, K. Kondo, T. Takeuchi, S. Mori, T. Kanda
5 2010
5
🐬